Testing a treatment target map in sudden brain bleeding
Part of Brain & nervous system, Heart & circulation clinical trials.
This study looks at a special scan (DSA, done with contrast dye) to find a likely “target” that doctors can use when treating sudden brain bleeding. It’s meant to help doctors better understand where treatment may be needed soon after symptoms start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sudden, non-traumatic brain bleeding (intracerebral hemorrhage) confirmed by a CT scan without dye
- You can start the DSA scan within 3 hours of symptom onset
- Your doctor agrees that the DSA scan is appropriate for you
- You (or an emergency process for consent) agree to take part in the study
- Your care team does not strongly suspect the bleeding came from an aneurysm or an arteriovenous malformation (or a condition called amyloid angiopathy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how inflammation and changes in the blood-brain barrier occur after a spontaneous brain bleed. Researchers use special brain imaging and scans to understand these processes, which may help improve treatment in the future.
This trial tests a non-invasive ultrasound device to help clear blood clots from the brain after a spontaneous bleed. It may be an option for people with small to medium-sized bleeds who do not need surgery.
This study tracks patients who have had sudden, severe bleeding in the brain and received minimally invasive surgery (a less-invasive surgical approach) to treat it. Researchers want to understand outcomes and improve treatment for this serious condition.
This study is for people who had a spontaneous brain bleed and did not have surgery. It aims to learn more about their recovery and health over time.
This study looks for markers in your blood and brain scans that may help doctors better understand and predict outcomes after a spontaneous brain bleed. It is for people with high blood pressure who have had a bleed within the last three days.
This trial tests a clot-busting drug called tenecteplase to see if it can safely treat a large brain bleed (intracerebral hemorrhage). It may help people who had a bleed within the last 24 hours and whose CT scans show the bleed has stopped growing.
Hear when a new Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.